IgA Responses to HPV-16 E2 Protein in Cervical Neoplasia
Author Information
Author(s): L Rocha-Zavaleta, D Jordan, S Pepper, G Corbitt, F Clarke, NJ Maitland, CM Sanders, JR Arrand, PL Stern, SN Stacey
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK
Hypothesis
The study investigates the association between serological IgA responses to the HPV E2 protein and the stages of cervical neoplasia.
Conclusion
The IgA antibody response to the E2 protein varies with the stage of cervical neoplasia, being higher in lower grades and lower in cervical carcinoma patients.
Supporting Evidence
- Serum IgA levels against the E2 protein were elevated in CIN patients relative to normal controls.
- Lower levels of IgA were observed in cervical carcinoma patients compared to CIN patients.
- The highest antibody levels were seen in lower grades of neoplasia up to CIN 2.
Takeaway
This study found that people with early stages of cervical neoplasia have higher levels of a specific antibody, but those with cervical cancer have lower levels.
Methodology
The study used enzyme-linked immunosorbent assays (ELISA) to detect IgG and IgA responses in serum samples from cervical neoplasia patients and controls.
Limitations
The study is cross-sectional and does not provide information on the kinetics of the IgA response over time.
Participant Demographics
The study included 45 cervical carcinoma patients, 27 non-genital cancer patients, and 72 colposcopy patients, with a range of ages from 21 to 74 years.
Statistical Information
P-Value
p<0.0002
Confidence Interval
95% confidence interval 4.2-254.3
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website